High-density lipoproteins: a novel therapeutic target for cardiovascular disease

References

• Carlson LA. Nicotinic acid and other therapies for raising high-density lipoprotein. Curr Opin Cardiol. 2006;21(4):336–344.
   Web of Science ®Google Scholar
• Evans M, Roberts A, Davies S, Rees A. Medical lipid-regulating therapy: Current evidence, ongoing trials and future developments. Drugs. 2004;64(11):1181–1196.
   Web of Science ®Google Scholar
• Venkatesh PK, Caskey D, Reddy PC. Therapies to increase high-density lipoprotein cholesterol and their effect on cardiovascular outcomes and regression of atherosclerosis. Am J Med Sci. 2008;336(1):64–68.
   Web of Science ®Google Scholar
• Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: Raising high-density lipoprotein cholesterol levels. Postgrad Med J. 2008;84(997):590–598.
   Web of Science ®Google Scholar
• Boden WE. Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management. Curr Opin Cardiol. 2003;18(4):278–285.
   PubMed Web of Science ®Google Scholar
• Fabbri G, Maggioni AP. Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us? Adv Ther. 2009;26(5):469–487.
   Web of Science ®Google Scholar
• Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C; European Consensus Panel on HDL-C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: The role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin. 2004;20(8):1253–1268.
   PubMed Web of Science ®Google Scholar
• Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: An idea whose time for testing is coming, part I. Circulation. 2001;104(19): 2376–2383.
   Web of Science ®Google Scholar
• Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality: The Framingham Heart Study. Arteriosclerosis. 1988;8(6):737–741.
   PubMedGoogle Scholar
• Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol. 1997;17(1):107–113.
   Web of Science ®Google Scholar
• Gordon DJ, Knoke J, Probstfield JL, Superko R, Tyroler HA. High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: The Lipid Research Clinics Coronary Primary Prevention Trial. Circulation. 1986;74(6):1217–1225.
   Web of Science ®Google Scholar
• Nurmohamed MT, Dijkmans BA. Dyslipidaemia, statins and rheumatoid arthritis. Ann Rheum Dis. 2009;68(4):453^55.
   Web of Science ®Google Scholar
• Badimon JJ, Ibanez B. Increasing high-density lipoprotein as a therapeutic target in atherothrombotic disease. Rev Esp Cardiol. 2010; 63(3):323–333. Spanish.
   Web of Science ®Google Scholar
• Cziraky MJ, Watson KE, Talbert RL. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm. 2008;14(8 Suppl):S3–S28.
   Web of Science ®Google Scholar
• Tenenbaum A, Fisman EZ, Motro M, Adler Y Optimal management of combined dyslipidemia: What have we behind statins monotherapy? Adv Cardiol. 2008;45:127–153.
   PubMed Web of Science ®Google Scholar
• Després JP, Lemieux I, Robins SJ. Role of fibric acid derivatives in the management of risk factors for coronary heart disease. Drugs. 2004; 64(19):2177–2198.
   PubMed Web of Science ®Google Scholar
• Davignon J. Advances in drug treatment of dyslipidemia: Focus on atorvastatin. Can J Cardiol. 1998;14 Suppl B:28B-38B.
   Web of Science ®Google Scholar
• Ashen MD, Blumenthal R. Low HDL cholesterol levels. NEngl J Med. 2005;353(12):1252–1260.
   Web of Science ®Google Scholar
• Brown BG, Zhao X-Q, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345(22):1583–1592.
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended- release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110(23):3512–3517.
   PubMed Web of Science ®Google Scholar
• Mahley RW, Bersot TP. Drug therapy for hypercholesterolemia and dyslipidemia. In: Brunton LL, Lazo SJ, Parker KL, editors. Goodman and Gilman ’s The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw Hill; 2006.
   Google Scholar
• Kreisberg RA. Diabetic dyslipidemia. Am J Cardiol. 1998;82(12A): 67U–73U.
   PubMed Web of Science ®Google Scholar
• Inder MS, Shishehbor MH, Ansell BJ. High density lipoprotein as a therapeutic target. JAMA. 2007;298(7):786–798.
   Web of Science ®Google Scholar
• Ou J, Ou Z, Jones DW, et al. L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation. 2003;107(18):2337–2341.
   PubMed Web of Science ®Google Scholar
• Tabet F, Remaley AT, Segaliny AI, et al. The 5 A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro. Arterioscler Thromb Vasc Biol. 2010;30(2):246–252.
   Web of Science ®Google Scholar
• Vaziri ND, Kim HJ, Moradi H, et al. Amelioration of nephropathy with apoA-1 mimetic peptide in apo-E deficient mice. Nephrol Dial Transplant. 2010;25(11):3525–3534.
   Web of Science ®Google Scholar
• Navab M, Anantharamaiah GM, Hama S, et al. D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol. 2005;25(7):1426–1432.
   PubMed Web of Science ®Google Scholar
• Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: A new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev. 2006;58(3):342–374.
   PubMed Web of Science ®Google Scholar
• Hunt JA, Lu Z. Cholesteryl ester transfer protein (CETP) inhibitors. Curr Top Med Chem. 2009;9(5):419^27.
   Web of Science ®Google Scholar
• Ranalletta M, Bierilo KK, Chen Y, et al. Biochemical characterization of cholesteryl ester transfer protein inhibitors. J Lipid Res. 2010;51(9): 2739–2752.
   Web of Science ®Google Scholar
• Stein EA, Roth EM, Rhyne JM, Burgess T, Kallend D, Robinson JG. Safety and tolerability of dalcetrapib (R04607381/JTT-705): Results from a 48-week trial. Eur Heart J. 2010;31(4):480^88.
   Web of Science ®Google Scholar
• Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: Two double-blind, randomised placebo-controlled phase I studies. Lancet. 2007;370(9603):1907–1914.
   Web of Science ®Google Scholar
• Tardif JC. Prevention challenges: The era of atherosclerosis regression. Can J Cardiol. 2006;22 Suppl C:27C-30C.
   Web of Science ®Google Scholar
• Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350(15):1505–1515.
   PubMed Web of Science ®Google Scholar
• Clark RW, Sutfin TA, Ruggeri RB, et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: An initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol. 2004;24(3):490–497.
   PubMed Web of Science ®Google Scholar
• Morehouse LA, Sugarman ED, Bourassa PA, et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand white rabbits. J Lipid Res. 2007;48(6): 1263–1272.
   PubMed Web of Science ®Google Scholar
• Meyers CD, Kashyap ML. Pharmacologic elevation of high-density lipoproteins: Recent insights on mechanism of action and atherosclerosis protection. Curr Opin Cardiol. 2004;19(4):366–373.
   Web of Science ®Google Scholar
• Shah PK. Apolipoprotein A-I/HDL infusion therapy for plaque stabilization-regression: A novel therapeutic approach. Curr Pharm Des. 2007;13(10):1031–1038.
   Web of Science ®Google Scholar
• Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: A systematic review. JAMA. 2007;298(7):786–798.
   PubMed Web of Science ®Google Scholar
• Cannon CP. High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome. Clin Cornerstone. 2007; 8 Suppl 6:S14–S23.
   Google Scholar